3D InSight™ | 3D In Vitro MASH Model for Screening and Target Validation
Screening for Metabolic dysfunction-associated steatohepatitis therapies in the only scalable human 3D in vitro MASH model for industry-ready application.
3D In Vitro MASH Model
MASH (Metabolic Dysfunction-associated Steatohepatitis, recently renamed from NASH) is a complex, multi-faceted disease, impacting more than 115 million people worldwide.
InSphero's 3d in vitro MASH model is designed to reflect the complexity of fatty liver disease. Our MASH Screening platform empowers you to simultaneously assess multiple disease parameters, including
- Steatosis
- Inflammation
- Fibrosis
Consequently, you and your team gain a more comprehensive understanding of your asset's impact and efficacy, enabling early-stage decision-making in your MASH research.
Why MASH Screening with InSphero?
Advance your research with our scalable 3D in vitro MASH model for life-changing therapies, improving the lives of patients worldwide.
Predictive and robust human 3D in vitro MASH model
As complex as necessary and as simple as possible - our research credo at work. Based on co-culturing disease-relevant primary cells, our model accurately mimics MASH
Continuity from screening to mechanistic research
Our MASH model is not only ideal for automated screening, but also perfect for mechanistic research
Understand the impact of genetic variants (SNPs)
3D InSight™ MASH model is available in multi-donor form or based on single donors, including MASH-relevant SNPs (e.g., PNPLA3, HSD17B13)
Simultaneously assess hallmarks of MASH and safety
In addition to providing dependable readouts for steatosis, inflammation, and fibrosis, our MASH model also provides valuable information on cytotoxicity and the therapeutic window
Join the MASH CALL Initiative February 2025
Benefit our scalable, reliable, and reproducible 3D in vitro MASH Model for:
- Increased throughput and automation
- Reduced costs for a unique solution
Our Process in MASH Screening
3D InSight™ Human Liver Microtissue formation
Primary human hepatocytes (PHHs), hepatic stellate cells (HSCs), Kupffer cells, and liver endothelial cells (LECs)
Lipid loading
Using an optimized treatment with free fatty acids and elevated sugar concentration
Compound dosing
Precise induction of the desired MASH phenotype followed by compound addition
Multiparametric readouts
Quantification of lipids, inflammation, and fibrosis using biochemical or imaging assays
MASH CALL Initiative | February 2025
Unlock the full potential of MASH Screening
We are pioneering the approach for drug discovery in MASH by launching a CALL with valuable insights into the:
- Anti-steatotic and anti-fibrotic effects of your compounds
- Comparison with clinical candidates and reference controls
Unlock the full potential of your research with:
✔️ Increased throughput and automation enabled by scalable 3D in vitro MASH Model
✔️ Reduced costs for a unique solution
